Quick Answer
Inhibrx Biosciences, Inc. reported Cash and Equivalents of $124.22 million for fiscal year 2025.
Inhibrx Biosciences, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $124.22M | -18.6% |
| 2024 | $152.60M | -45.1% |
| 2023 | $277.92M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $153.09M | -22.0% | -17.9% |
| June 30, 2025 | $186.57M | -17.8% | -13.8% |
| March 31, 2025 | $216.52M | — | +41.9% |
| December 31, 2024 | $152.60M | -45.1% | -22.3% |
| September 30, 2024 | $196.33M | — | -13.5% |
| June 30, 2024 | $226.86M | — | -18.4% |
| December 31, 2023 | $277.92M | — | — |
- Inhibrx Biosciences, Inc. showed a decrease of -18.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2025 period, Inhibrx Biosciences, Inc.’s cash and equivalents has declined by 55.3% (from $277.92 million to $124.22 million).
- The most recent figure is from Inhibrx Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: